# Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Hepatocellular Carcinoma (HCC)

> **NCT00484211** · PHASE2 · COMPLETED · sponsor: **AGC Biologics S.p.A.** · enrollment: 40 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** NGR-hTNF

## Key facts

- **NCT ID:** NCT00484211
- **Lead sponsor:** AGC Biologics S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12
- **Primary completion:** 2011-11
- **Final completion:** 2013-04
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2014-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00484211

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00484211, "Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Hepatocellular Carcinoma (HCC)". Retrieved via AI Analytics 2026-09-09 from https://api.ai-analytics.org/clinical/NCT00484211. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*